Please select the option that best describes you:
Topics:
Hematologic Malignancies • Medical Oncology • Leukemia • Internal Medicine • CLL • Hematology
Do you ever discontinue ibrutinib in patients with CLL who have a good response?
For instance, would you discontinue when there is resolution of adenopathy and normalization of counts? If so, do you overlap ibrutinib with other therapies to avoid rebound or relapse?
Answer from: Medical Oncologist at Academic Institution
For patients who are responding well to ibrutinib and tolerating the drug well, I do not discontinue ibrutinib. The clinical trials of single agent BTK inhibitors have all continued therapy indefinitely, which is a logical approach considering that very few will attain minimal residual disease negat...
Sign in or Register to read more